Doug Fulling, MA, and Andrew Cournoyer, MBA, discuss how patients could benefit from payers learning more about a new drug by joining clinical trials earlier.
Doug Fulling, MA, president of Precision AQ, and Andrew Cournoyer, MBA, senior vice president and director of the access experience team, Precision AQ, spoke with The American Journal of Managed Care® about how introducing payers into clinical spaces earlier could benefit their patients.
This transcript has been lightly edited for clarity.
Transcript
How can patients benefit from payers being introduced into clinical trials earlier?
Doug Fulling: One of the big focuses in clinical research is to diversify the patient populations that actually participate in clinical research. And if you think about payers, they have access and exposure to those diverse patient populations. So by working closely with them during the clinical trial, we have the ability to focus on making sure that there's a true representation of the US population, for those clinical trials through payers who can identify diverse patient populations. So that's number 1.
Number 2, is not everybody has access to a clinical trial. There are limitations on where research is done, and we believe that payers can be the missing link in connecting patients who might be eligible to facilities that are actually running these clinical trials. There's a big gap in how many people actually have the opportunity to participate.
Those are where there's opportunities for patients. It's really in diversifying the clinical research and giving those populations that wouldn't necessarily have accessibility to those trials and then also just broadening the education and the awareness of clinical trials that are taking place in the market.
Andrew Cournoyer: On that education front, there might be one other thing that payers have an opportunity to support, because they have a large team of case management or case managers, or they are individuals who are making direct patient contact or out in the field. When it comes to a clinical trial, there's a lot of stigma associated with them that's kind of a treatment of last resort. And that's not usually the case, actually. It's getting someone involved earlier, like we were saying earlier, may actually drive a better outcome quicker soonere and then ultimately a better quality of life for that patient.
I think payers are in a unique position to help educate their members or patients, if you will, about the benefits of clinical trials to help remove some of the stigmas in the adoption. There are certainly a number of health disparities and social determinants of health that are negatively impacting the certain trust factors that go into patients entering into trials. And that might also be an opportunity for payers who have, in some cases, very broad reach to reach out and help remove some of those barriers.
New Research Challenges Assumptions About Hospital-Physician Integration, Medicare Patient Mix
April 22nd 2025On this episode of Managed Care Cast, Brady Post, PhD, lead author of a study published in the April 2025 issue of The American Journal of Managed Care®, challenges the claim that hospital-employed physicians serve a more complex patient mix.
Listen
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
Symptom Documentation Differences in Acute Cancer Care Suggest Sociodemographic Disparities
April 22nd 2025Researchers are calling for more targeted efforts to improve health equity after a new analysis revealed that cancer symptom documentation and burden vary across certain demographics.
Read More